Risk of autoimmune skin and connective tissue disorders after mRNA-based COVID-19 vaccination - 16/09/23
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
Data on the association between the development of autoimmune diseases and COVID-19 vaccination are limited.
Objective |
To investigate the incidence and risk of autoimmune connective tissue disorders following mRNA-based COVID-19 vaccination.
Methods |
This nationwide population-based study was conducted in South Korea. Individuals who received vaccination between September 8, 2020-December 31, 2021, were identified. Historical prepandemic controls were matched for age and sex in 1:1 ratio. The incidence rate and risk of disease outcomes were compared.
Results |
A total of 3,838,120 vaccinated individuals and 3,834,804 controls without evidence of COVID-19 were included. The risk of alopecia areata, alopecia totalis, primary cicatricial alopecia, psoriasis, vitiligo, anti-neutrophil cytoplasmic antibody-associated vasculitis, sarcoidosis, Behcet disease, Crohn disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, Sjogren syndrome, ankylosing spondylitis, dermato/polymyositis, and bullous pemphigoid was not significantly higher in vaccinated individuals than in controls. The risk was comparable according to age, sex, type of mRNA-based vaccine, and cross-vaccination status.
Limitations |
Possible selection bias and residual confounders.
Conclusion |
These findings suggest that most autoimmune connective tissue disorders are not associated with a significant increase in risk. However, caution is necessary when interpreting results for rare outcomes due to limited statistical power.
Le texte complet de cet article est disponible en PDF.Key words : autoimmune disease, connective tissue disease, COVID-19, epidemiology, mRNA, risk, skin disease, vaccination
Abbreviations used : AA, aHR, ANCA, CI, COVID-19, ICD-10, NHIS, SARS-CoV-2
Plan
| Funding sources: This research was supported by a fund from the research program of the Korea Medical Institute and a National Research Foundation (NRF) of Korea grant funded by the Korea government (MSIT) (no. 2017R1A5A2015369). |
|
| IRB approval status: This study was approved by the Korean National Institute for Bioethics Policy (NHIS-2022-1-496) and a waiver of informed consent was granted owing to the deidentified data used. |
Vol 89 - N° 4
P. 685-693 - octobre 2023 Retour au numéro
Article précédent
- Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: A Randomized Controlled Trial in a real-world setting
- Pim Aarts, Johanna C. van Huijstee, Hessel H. van der Zee, Martijn B.A. van Doorn, Kelsey R. van Straalen, Errol P. Prens
- A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa
- Rebecca Jepsen, Chloe Edwards, Akshay Flora, Emily Kozera, John W. Frew
Bienvenue sur EM-consulte, la référence des professionnels de santé.